GE HealthCare Q2 Orders Surge 11%, Guides Above Street; Shares Jump 12%
GEHC sits 22% above its 52-week low of $58.75.
Summary
GE HealthCare delivered a strong Q2 with orders up 11%, well above mid-single-digit expectations, driving revenue to $5.3B and adjusted EPS of $1.13, beating consensus. The beat was broad-based, led by Advanced Imaging Solutions (+7.9%) and Pharmaceutical Diagnostics (+16%), while Patient Care Solutions revenue fell 13% and is now under strategic review, including a potential sale. Management issued Q3 guidance for 3-4% organic revenue growth and low-double-digit adjusted EPS growth, and reaffirmed full-year outlook. Shares surged 12%, on pace for a record daily gain, though still down ~13% YTD. This follows the CFO departure announced last week and the earlier securities fraud investigation, adding a positive operational counterpoint.
At the time of this announcement, GEHC was trading at $71.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $32.6B. The 52-week trading range was $58.75 to $89.77. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.